article Open AccessTop 1% cited
Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology · 2020 · Vol. 31(7) · pp. 844–860
Marianne Pavel✉(Universitätsklinikum Erlangen)Kjell Öberg(Uppsala University)M. Falconi(Vita-Salute San Raffaele University)E. P. Krenning(Cyclotron (Netherlands))Anders Sundin(Uppsala University)Aurel Perren(University of Bern)Alfredo Berruti(University of Brescia)
Neuroendocrine Tumor Research AdvancesLung Cancer Research StudiesNeuroblastoma Research and TreatmentsMedicineGuidelineClinical PracticeMultidisciplinary approachMedical physicsNeuroendocrine tumorsIntensive care medicineFamily medicineInternal medicinePathology
MeSH terms
Follow-Up StudiesGastrointestinal NeoplasmsHumansIntestinal NeoplasmsPancreatic NeoplasmsStomach NeoplasmsNeuroendocrine TumorsKi-67 Antigen
Funding
- Pfizer
- Bayer
- Ipsen Biopharmaceuticals
- Advanced Accelerator Applications
- Astellas Pharma
- European Society for Medical Oncology
- Ipsen
- Novartis Pharma
- Janssen Biotech
Citations
1,102
FWCI
86.11
field-weighted impact
References
105
Percentile
100%
vs. same field & year
Citations per year
References
Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours
Alimentary Pharmacology & Therapeutics · 2009 · 404 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.